ESHB 2196
In CommitteeHouse
PANDAS, pediatric treatment
Expanding access to PANDA PANS treatment.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill requires most private health insurance plans in Washington to cover intravenous immunoglobulin (IVIG) therapy for children with PANDAS or PANS, under specific medical criteria. It also restricts insurers from imposing certain barriers to coverage, such as requiring less effective treatments first or denying coverage based on prior diagnoses.
- Requires health insurance plans (excluding certain public employee plans) issued or renewed on or after January 1, 2027, to cover three initial monthly courses of intravenous immunoglobulin (IVIG) therapy for PANDAS/PANS, and additional courses if medically necessary.
- Coverage is only required if patients have tried and failed two less intensive treatments (e.g., they were not effective, not tolerated, or did not improve symptoms), as measured by a validated tool.
- Prohibits insurers from denying coverage based on prior treatments, previous diagnoses (including under different names like autoimmune encephalopathy), or patient age.
- Requires insurers to allow reevaluation every three months to continue coverage of IVIG therapy.
- Bars insurers from requiring patients to try treatments that only address psychiatric symptoms before covering IVIG, and from denying coverage for out-of-state care if not available in Washington.
Who is affected
- Children and families affected by PANDAS/PANS — Children and adolescents diagnosed with PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections) or PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) who may need access to specialized treatment like intravenous immunoglobulin (IVIG) therapy.
- Healthcare providers treating PANDAS/PANS — Pediatric neurologists, psychiatrists, and other clinicians who treat children with PANDAS/PANS and will need to follow new coverage rules when recommending or delivering care.
- Health insurance carriers — Insurance companies (health carriers) operating in Washington must now cover certain IVIG treatments under specific conditions, and must follow new rules about prior treatments, reevaluations, and coverage denials.
- State health agencies — State agencies and public health entities may be involved in oversight or implementation, especially as the bill adds to the administrative code under chapter 48.43 RCW.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Guarantees coverage of up to three initial monthly IVIG courses for PANDAS/PANS — a rare, severely disabling condition with limited treatment options — significantly improving access to a potentially life-altering therapy for children who otherwise may be denied care or face years-long coverage battles.
HealthcarePeopleRef: Sec. 1(1)Bars insurers from requiring prior trials of psychiatric-only treatments (e.g., SSRIs, CBT) before covering immunomodulatory IVIG, preventing misdirected or ineffective care and reducing diagnostic delay — a common problem for families navigating psychiatric vs. neurological attribution.
HealthcarePeopleRef: Sec. 1(3)(c)Prohibits denial of coverage based on prior diagnoses or alternative names (e.g., autoimmune encephalopathy), addressing historical underdiagnosis and ensuring continuity of care for children whose symptoms evolved or were previously mislabeled.
HealthcarePeopleRef: Sec. 1(3)(a)Requires coverage of out-of-state IVIG if unavailable in Washington — critical for families in rural or underserved areas where pediatric neurologists or infusion centers are scarce, reducing travel burden and treatment delays.
HealthcarePeopleRef: Sec. 1(3)(d)Bars age-based denials, ensuring adolescents and older children (up to age 21 in many PANS/PANDAS cases) are not excluded from coverage based on arbitrary age cutoffs — aligning coverage with clinical reality of disorder persistence.
HealthcarePeopleRef: Sec. 1(3)(e)
Potential Concerns (5)
Requires insurers to cover IVIG only after patients fail two prior, less-intensive treatments — potentially delaying access to potentially effective care for children with acute neuropsychiatric symptoms, which may worsen outcomes during critical developmental windows.
HealthcarePeopleRef: Sec. 1(1)(a)Mandates three-month reevaluations to continue coverage, which may create administrative burden for families and providers and risk coverage gaps if reevaluations are delayed — potentially disrupting continuity of care for vulnerable children.
HealthcareLean peopleRef: Sec. 1(2)Excludes public employee health plans (under chapter 41.05 RCW) from the coverage requirement, creating inequity in access — children enrolled in those plans may be left without guaranteed coverage despite identical medical need.
HealthcarePeopleRef: Sec. 1(1)(a)Unquantified increase in state healthcare costs may pressure premiums or require offsetting budget reallocations, potentially affecting public programs or leading to cost-shifting to families through higher deductibles or copays.
FinancialLean peopleRef: Fiscal Impact section (not quantified)The requirement to use a “validated instrument” to measure improvement may exclude children whose symptoms improve in ways not captured by current tools — potentially denying coverage to patients who are clinically improving but not meeting narrow metric thresholds.
HealthcareLean peopleRef: Sec. 1(1)(a)
Who Is Most Affected
Children with PANDAS/PANS and their families — especially those with limited financial means — stand to gain dramatically: IVIG is often the only effective treatment, but costs $20,000–$60,000/year out-of-pocket. This bill removes insurance barriers that have historically forced families into bankruptcy or care deserts.
Providers gain clarity and authority to treat based on clinical need rather than insurer gatekeeping; however, they face new administrative duties (e.g., documenting failed trials using validated tools) and may still contend with prior authorization delays or inconsistent insurer interpretation.
Insurers face new coverage obligations and administrative costs (e.g., reevaluations, out-of-state coordination), but the scope is narrow (only PANDAS/PANS, only IVIG, only after failed trials) — limiting financial exposure. Large national carriers may absorb costs more easily than small regional plans.
State agencies (e.g., DOH, OCI) will need to monitor compliance and potentially update guidance — adding modest administrative burden but reinforcing consumer protection in a historically unregulated area of pediatric neuroimmunology.
Rural families and those in health professional shortage areas benefit from out-of-state coverage and reduced need for long-distance travel — but may still face disparities if local infusion centers lack pediatric expertise or capacity.